Literature DB >> 11466380

Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites.

A A Horner1, S K Datta, K Takabayashi, I M Belyakov, T Hayashi, N Cinman, M D Nguyen, J H Van Uden, J A Berzofsky, D D Richman, E Raz.   

Abstract

Immunostimulatory DNA sequences (ISS, also known as CpG motifs) are pathogen-associated molecular patterns that are potent stimulators of innate immunity. We tested the ability of ISS to act as an immunostimulatory pathogen-associated molecular pattern in a model HIV vaccine using gp120 envelope protein as the Ag. Mice immunized with gp120 and ISS, or a gp120:ISS conjugate, developed gp120-specific immune responses which included: 1) Ab production; 2) a Th1-biased cytokine response; 3) the secretion of beta-chemokines, which are known to inhibit the use of the CCR5 coreceptor by HIV; 4) CTL activity; 5) mucosal immune responses; and 6) CD8 T cell responses that were independent of CD4 T cell help. Based on these results, ISS-based immunization holds promise for the development of an effective preventive and therapeutic HIV vaccine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11466380     DOI: 10.4049/jimmunol.167.3.1584

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus.

Authors:  Sang-Moo Kang; Richard W Compans
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.

Authors:  Bishnu P Nayak; Gangadhara Sailaja; Abdul M Jabbar
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

3.  Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells.

Authors:  Igor M Belyakov; Scott A Hammond; Jeffrey D Ahlers; Gregory M Glenn; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

4.  Dendritic cell targeted vaccines: Recent progresses and challenges.

Authors:  Pengfei Chen; Xinsheng Liu; Yuefeng Sun; Peng Zhou; Yonglu Wang; Yongguang Zhang
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

5.  Investigations into the efficacy of multi-component cocaine vaccines.

Authors:  Atsushi Kimishima; Margaret E Olson; Kim D Janda
Journal:  Bioorg Med Chem Lett       Date:  2017-12-20       Impact factor: 2.823

Review 6.  Induction of antigen cross-presentation by Toll-like receptors.

Authors:  Sandip K Datta; Eyal Raz
Journal:  Springer Semin Immunopathol       Date:  2004-10-14

7.  Memory T cells persisting in the brain following MCMV infection induce long-term microglial activation via interferon-γ.

Authors:  Manohar B Mutnal; Shuxian Hu; Morgan R Little; James R Lokensgard
Journal:  J Neurovirol       Date:  2011-07-29       Impact factor: 2.643

Review 8.  Dendritic cell-targeted vaccines--hope or hype?

Authors:  Wolfgang Kastenmüller; Kathrin Kastenmüller; Christian Kurts; Robert A Seder
Journal:  Nat Rev Immunol       Date:  2014-09-05       Impact factor: 53.106

Review 9.  Progress on new vaccine strategies against chronic viral infections.

Authors:  Jay A Berzofsky; Jeffrey D Ahlers; John Janik; John Morris; SangKon Oh; Masaki Terabe; Igor M Belyakov
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

10.  Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.

Authors:  Petra Mooij; Ivonne G Nieuwenhuis; Christiaan J Knoop; Robert W Doms; Willy M J M Bogers; Peter J F Ten Haaft; Henk Niphuis; Wim Koornstra; Kurt Bieler; Josef Köstler; Brør Morein; Aurelio Cafaro; Barbara Ensoli; Ralf Wagner; Jonathan L Heeney
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.